Biomedicine and life health industry is the development direction that Shenzhen Municipal Party Committee attaches great importance to. Shenzhen Wanle Pharmaceutical Co., Ltd. (hereinafter referred to as “Wanle Pharmaceuticalâ€) is a star enterprise in Shenzhen. Since its establishment in 1990, it has been committed to anti-tumor drugs. R & D, production and sales have formed a rich and comprehensive product structure, and established a specialized research and development and industrialization base for anti-tumor medicines. Deep cultivation of large and small molecules, multiple cancers are involved With the high incidence of tumor diseases, anticancer drugs have become a hotspot in the field of pharmaceutical research and development and drug innovation. Yuan Qing said that in order to overcome cancer at an early date, the pharmaceutical industry has consciously concentrated resources on researching anticancer drugs to meet the needs of patients. Moreover, there is no drug that can be cured in the field of cancer so far. As long as it is better than the drugs already on the market, it is in line with the basic principles of drug review and listing. Compared with the relatively mature areas such as hypertension and diabetes, anticancer drugs It's easier to go public. On the other hand, although the drug development cycle is long, anticancer drugs may invest more and have higher risks. However, once the drugs are listed, they will produce huge social and economic benefits, which also stimulates the enthusiasm of pharmaceutical companies for research and development of anticancer drugs. It is understood that Wanle Pharmaceutical's R&D principle does not start from the source, but rather takes more and less investment and takes less time. "One is the combination of imitation and creation, and it is modified on the basis of originality; the second is to introduce relatively mature projects at home and abroad to carry out further development; the third is to directly purchase products, and has already introduced some from Japan, Europe and other countries. Product." Yuan Qing said. After more than 20 years of development, Wanle Pharmaceuticals has owned major categories including anthracycline antibiotics, plant alkalis (including taxanes, camptothecins and vinblastines), alkylating agents, and metal platinum. Anti-tumor drugs. In the treatment of major malignant tumors such as hematological tumors, urinary system tumors, breast cancer, and lung cancer, it has established its own brand system. In addition, it has also entered the development of chemical small molecule targeted drugs, anti-tumor adjuvant therapy drugs, anti-metabolites, hormone antagonists and monoclonal antibody drugs. Respond to national policies in response to national policies On September 11, the National Pilot Joint Procurement Office held a working symposium in Shanghai. The Medical Insurance Bureau determined the requirements and operators of the joint procurement, and announced the first batch of procurement lists. When this news came out, it caused widespread panic in the medical profession. Yuan Qing said that several varieties of Wanle Pharmaceutical are conducting research on consistency evaluation. Although these varieties are not the varieties in the “289 Catalogueâ€, they are likely to be the next major focus of the country. "For various reasons, there is a certain gap between generic drugs and original drugs. From the national level, it is hoped that domestic generic drugs can meet the efficacy and treatment requirements of the original drugs as soon as possible to ensure that ordinary Chinese people are safe. Generic drugs are unquestionable decisions. Many pharmaceutical companies are aware of this problem and take the initiative to respond to the country's call for generic drug conformity evaluation. However, the recent procurement plan may cause some enterprises to lose motivation and confidence. Said. Yuan Qing believes that the purchase of quantity is actually a product that is exchanged for price and spends a lot of energy and funds to pass the consistency evaluation. The final price is not similar to the original drug, nor is it higher than other generic drugs, even more than the original. The price is even lower. In particular, the price of medicines in pilot cities will drive the linkage of drug prices in other cities. This is a phenomenon that many pharmaceutical companies do not want to see. “From a national perspective, in order to reduce medical insurance costs, lower drug prices, and benefit more patients, this is a solution. However, for pharmaceutical companies, today’s R&D and production costs are already high, and the price reduction is not a big one. Good news," Yuan Qing said. Single Use Trocar Site Closure Device A fascial closure device is a laparoscopic instrument used to close the fascia, the layer of tissue that covers and separates abdominal organs and muscles. The device is used during laparoscopic surgery to create a secure closure of the fascia after the surgical procedure is complete.
The use of fascial closure devices during laparoscopic surgery can help reduce the risk of postoperative complications such as hernias, wound infections, and intestinal obstruction. It also closes the fascia more quickly and efficiently, reducing the overall time required for the procedure.
Single Use Trocar Site Closure Device,Medical Use Fascial Closure System,Single Use Fascial Closure System,Exit Fascia Closure Device Changzhou Weipu Medical Devices Co., Ltd. , https://www.wmlaparoscopic.com
The fascial closure device consists of a needle and suture material attached to a handle. A needle is used to puncture the fascia, then suture material is passed through the puncture site and tied tightly to close the fascia. The device's handle is used to control the movement of the needle and suture material, allowing precise placement and closure of the fascia.